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Ever since the introduction of the concept of Tissue Engineering, the field has developed 
and matured from a hype to a proper scientific discipline. Recently, the field is witnessing a 
reversal of the innovation drivers as it has started to move from a technology-driven 
science-focused field towards a patient-driven manufacturing-focused one. This evolution 
is made possible through innovations at the interface between biology and technology, 
including robust biological building blocks, precise biomanufacturing technologies, in-
depth characterization methods and in silico models. Combining this with novel insights in 
TE-related regulatory sciences and business strategies, the field is ready to meet the grand 
challenge of designing, developing and delivering living implants with the accuracy and 
robustness expected from inanimate implants, leading to sustainable, predictable and 
vastly superior biological and clinical results.  
 
Impact Statement  
In this perspective we discuss the different stages of development the Tissue Engineering 
(TE) field has gone through in its relatively young history. We discuss how TE is evolving 
from a technology-driven, science-focused field towards a patient-driven, manufacturing-
focused one where patients’ needs are translated into production process requirements, 
and subsequently into technological and biological innovations needed to meet the 




























































































































































































Undoubtedly, the interdisciplinary field of Tissue Engineering (TE) has made vast progress 
since it was coined in the mid-eighties, undergoing a dramatic technological but also 
conceptual evolution. However, to date there is still a lack of a widespread 
implementation of TE therapeutics in clinics  with only four TE products having obtained 
to date official marketing authorisation in the EU. These are Spherox (CO.DON), Holoclar 
(Chiesi Farmaceutici), MACI (Vericel) and Chondrocelect (TiGenix), however, the last two 
products are no longer authorised or have been suspended [1]. This demonstrates that 
there is still considerable progress to be made before a systematic and consistent 
pipeline of TE products to the clinic can be established.  
A historic perspective  
In the relatively young history of TE, roughly three periods can be distinguished (Figure 
1).  
The first era of TE (~ 1985-2000) is a perfect example of the brazenness that is typical 
for young and highly innovative fields. As any new technology or field going through the 
Gartner hype cycle, the first phase was characterised by bold claims and inflated 
expectations. Large investments were made in start-ups with the aim of making it to the 
clinics by the turn of the century.  However, these promises were too high and the 
suggested clinical introduction was not realistic. Furthermore, the challenge of creating 
living implants was ill-defined at the time and the teams approaching the challenge 
were still deeply embedded in their respective disciplines, be it on the technology or the 
biology side.  The main innovation drivers were technological (mostly related to 
biomaterials) or biological (mostly related to stem cells) innovations from the respective 
disciplines. Around the 2000s, many of these start-ups had failed or folded and the field 
was going through the ‘trough of disillusionment’ (cf. Gartner hype cycle) [2].  However, 
in academia, the TE field continued its evolution into a distinct scientific field with its 
own community and jargon.  The second era of TE (~2000-2015) can be described as the 
coming of age of TE as a scientific discipline, finally overcoming some of the major 


























































































































































































that could be described as the first real tissue engineers, able to cross the lines between 
the different disciplines. Paradigms were questioned and alternatives such as 
Developmental Engineering [3,4] were proposed while major breakthroughs in 
technologies such as the development of the induced pluripotent stem cell (iPS) 
technology [5], gene editing [6] and bioprinting [7,8] provided, from different angles, 
unprecedented possibilities. However, this increased quality was not yet translating into 
a tangible impact on patients’ lives. This growing realisation meant that TE started 
entering a new phase, one that sees the reversal of the innovation drivers. The 
innovation drivers are no longer the developments in individual disciplines but rather 
the needs of the patient (Figure 2). In order to reach the patient, products need to 
possess a set of quality attributes that ensure product potency while they should be 
engineered in a robust manufacturing process guaranteeing the quality of the resulting 
product. For this to happen, innovations are needed in terms of developing robust 
biological building blocks – tissue structures, precise manufacturing technologies and 
high-throughput quality control (QC) tools. Recent developments in these areas, 
discussed in more detail in the following sections, contribute to an increase in the 
capacity of the entire field to produce potent and clinically relevant healthcare 
solutions.  
Starting from a clear identification of the patients’ needs, bearing in mind the 
manufacturing requirements, means the grand challenge for the third era of TE is to 
design, develop and deliver living implants with the accuracy and robustness we expect 
from inanimate implants, leading to predictable and vastly superior biological and clinical 
results. In order to tackle this grand challenge, technological and biological advances are 
required. In the second part of this perspective we will highlight a number of these 
advances and discuss their role in the global picture of TE.  
From technological and biological advances … 
Developmental Engineering  
Developmental engineering (DE) refers to the use of developmental processes as blueprint 


























































































































































































robustness.  In mimicking these processes, the aspiration is to overcome the current lack 
of quantitative metrics able to capture the degree of phenotypic progression that could 
forecast final TE product potency. Hence, concepts such as ‘developmental engineering’ 
[3,4], ‘engineered tissues as organ germs’ [9] and ‘reverse engineering development’ [10] 
are gaining ground. This allows for a gradual transition from the top-down question of 
“what is a biomimetic combination of cells-material-growth factor closely mimicking a 
target tissue” to a bottom-up question of “how can key developmental niches be 
accurately dissected, designed and precisely biomanufactured at the correct length scales 
into efficacious TE products”.  
Qualitative examples of the DE approach have been successfully provided, for instance in 
bone tissue engineering, where cartilage intermediate templates have been shown to give 
rise to bone ossicles through endochondral ossification. The DE approach was also applied 
successfully using both adult [11,12] and embryonic [13,14] stem cell sources and both 
scaffold-free and scaffold-based approaches [15,16], demonstrating the robustness of this 
paradigm. However, to date, it has not yet been demonstrated that TE implants can guide 
regeneration in vivo, leading to an outcome where contaminating tissue structures are 
absent (contaminating tissues are tissues unrelated to the regenerative context and not 
contributing to TE product potency). In addition, engineered TE products possessing a 
hierarchically complex structure able to perform dual (or more) regenerative tasks upon 
implantation remain elusive.  Scalable production of tissue modules that can guide 
regenerative events upon implantation is thus an important hallmark for the next 
generation of TE products.   
In-depth Characterisation Technologies – Single cell analysis and molecular 
characterization 
“You are as good an engineer as quality controls allow you to be”. One of the most 
important ongoing activities is the development of the analytics toolbox of the field. At the 
top of this, single cell genomics revolutionized the way we view cell populations. It 
provides a window into developmental cascades and tissue composition at the cell scale. 


























































































































































































along developmental cascades will provide an unprecedented compass for the design of TE 
products. However, TE is more than single cells and hence technologies that can provide 
insight in the molecular composition and architecture of extracellular matrices are equally 
needed. Quantitative Raman imaging represents a novel label-free method that enables 
visualization of 3D cell morphology and volumetric quantification of biomolecular 
structures with submicron-size detail [17]. This provides, amongst others, an excellent 
tool for deciphering ECM in terms of its molecular properties. For example, for native 
and engineered cartilage tissue Quantitative Raman imaging allowed a quantitative 
analysis of the distribution and organization of ECM constituents [18]. In addition, 
advances in nanoCT imaging allow for the 3D representation of the structural organization 
of complex tissues. For example, recently mineralized bone, bone marrow vasculature and 
adipose tissue can be detected simultaneously in 3D, providing insight in the design 
principles that complex bone TE constructs should possess to capture interactions 
between these three tissues [19].  Contrast enhanced nanoCT has furthermore produced 
insights at the nano-scale providing architectural information on tissue complexity [20]. 
Taken together, the TE field possesses a toolbox that captures ever more accurately the 
native tissue composition, structure, complexity and organization. These technologies 
allow deciphering in situ regenerative events and developmental cascades, providing a 
high-resolution picture of the properties that TE products should possess in order to 
exhibit regenerative properties. These technologies could therefore lead to precise 
characterization of the mechanisms of action of future TE products and their 
corresponding critical quality profile, essential for manufacturing processes described in 
the following section. 
High-precision, scalable biomanufacturing 
Biofabrication technologies able to operate with ever-increasing resolution and precision, 
provide an unprecedented opportunity for building tissues of increased complexity with a 
single molecule, cell, niche resolution comparable to that encountered in native tissues 
[21,22]. Examples of this enhancement in biomanufacturing capacity are the development 
of melt electrowriting [23], stereolithography [24] and laser-assisted  technologies [25], all 


























































































































































































possess the capacity to manipulate tissue modules such as single spheroids and positioning 
them in pre-ordered grids allowing them to fuse [26] or deposit them in printed scaffolds 
[27]. The ability to reproduce accurately CAD-based designs allows the incorporation of 
automation principles during production, although to date there are limited online QC 
methodologies that could validate the comparability between ‘as-designed’ and ‘as-
produced’ products. In addition, technical bottlenecks such as the production of 
vascularized, multi-centimeter sized implants will require the combined use of the 
aforementioned technologies now that successful proof of concept has been generated for 
endochondral bone repair [28,29]. The potential to build larger tissue structures based on 
robust modules, i.e. following a robust biological paradigm, produced through robust 
manufacturing processes and possessing a defined set of quality attributes, allows the 
implementation of Quality by Design in TE manufacturing [30] using the quality 
characterization methodologies described earlier. 
In silico toolbox – digital twins of intracellular gene regulation to bioreactor biology. 
As described above, the TE field is evolving into adopting solid biologic paradigms that 
provide robust biological building blocks, high precision biofabrication technologies that 
can use these building blocks to construct TE products and unprecedented quality 
characterization technologies that allow to assess the quality during and after production. 
Another enabling technology that could play an important role in establishing the 
systematic pipeline of TE products to the clinics, is in silico modeling. In silico is a term that 
was coined in analogy to the terms in vitro and in vivo, it is derived from the word silicium 
being the main component of computer chips and refers to computer modeling and 
simulation. In line with the Industry 4.0 concept, being the current trend of automation 
and data exchange in manufacturing technologies, digital twins can be created of every 
step of the TE production process [31]. Digital twins are digital replicas (computer models) 
of physical entities (e.g. process steps) that exchange information with their physical 
counterpart through sensors or historic data and that can be used to unable understanding 
and optimization of the physical process they represent. Intracellular gene regulatory 
models [32,33] are capable of reducing the in vitro large-scale screening to optimize 


























































































































































































subsequent maturation process in the bioreactor [35,36] allow for an optimization of these 
processes with a minimum of trial and error. Verification, validation and uncertainty 
quantification are key principles in building credibility for these models [37]. These digital 
twins can be connected in silico to form a digital TE pipeline and identify the crucial 
process steps and QC checks that guarantee high quality and predictable products. This 
provides a unique context for the production of in silico designed TE products where the 
appropriate quality attributes necessary for their functionality could be inbuilt. This way, in 
silico models guide the way from robust biological building blocks to a high-quality 
production process. 
… to innovation in regulation and business 
The biological and technological advances discussed in the previous section are by no 
means an exhaustive summary - think e.g. about advances in the incorporation of immune 
engineering requirements in TE products and renewable cell sources such as iPS cells,  that 
have not been included in this perspective but are discussed elsewhere [5,38]. What is 
striking in the discussed examples is the joined involvement of both engineering and 
biological disciplines. Addressing the TE grand challenge requires true integration of all 
disciplines involved, transcending the individual disciplines and establishing TE as a 
transdisciplinary scientific domain.  Simultaneously, it has become quite clear that the 
innovation is not only needed on the R&D side. TE solutions are inherently more 
complex and personalized than most pharmaceuticals and hence require tailor-made 
regulatory assessment, clinical trial design and business approaches.  
On the regulatory side, it is important to involve regulatory bodies early on in the design 
and development of TE products [2].  In order to pass regulatory scrutiny, these TE 
products should be well-characterised, robust, with consistent efficacy and an 
acceptable and controlled positive benefit/risk ratio. As argued in the previous section, 
enabling technologies can play a key-role in meeting those demands.  
With respect to the design of clinical trials for TE products, the one-size-fits-all, large 
randomized clinical trials are no longer in line with the current scientific, clinical and 


























































































































































































commercial/financial consequences [2]. An evolution has started towards more 
innovative, efficient and adaptive trial designs [39], built around active participation of 
patients and patient organisations.  Adaptive clinical trials, irrespective of the trial phase, 
use the results accumulated in the trial to modify the trial’s course in accordance with 
pre-specified rules [40].  It is furthermore important to de-risk the execution of clinical 
trials, especially in Phase III, by carefully analysing the risks of the trial execution and by 
a continuously surveillance of the quality of data being collected [2].  
On the business end of the spectrum, innovation is required to cope with the 
challenging combination of complexity and limited production volumes [41].  Principles 
such as design-to-cost [42] will become essential for the manufacturing of high-tech 
medical products such as TE implants. Design-to-cost is a management strategy 
designed to achieve an affordable product by targeting the manufacturing cost as an 
independent design parameter that must be met during product development.  This 
strategy guarantees that at the end of the R&D process, the developed product can be 
manufactured at a cost that is not prohibitive to its clinical uptake and penetration in 
the market. The rigorous quality assessment, scalable manufacturing technologies and 
in silico models described in the previous section, are elements that are crucial for 
reaching the design-to-cost objectives. 
Conclusion 
Starting from a clear identification of the patients’ needs and the manufacturing 
requirements of the corresponding TE solutions, the need for specific biological and 
technological advances can be identified. The capacity to design and build tissues with 
predictive performance thanks to these technological and biological advances, will result in 
a high quality and robust TE production process and resulting product. This will facilitate 
approval from regulatory bodies while attracting investments by lowering risks associated 
to market-stage product failure and hence will contribute to a novel viable medical sector 
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Figure 1: The three eras of Tissue Engineering. The years indicated in the figure are 




























































































































































































Figure 2: Reversing the innovation drivers. Originally being technology driven and science 
focused, the TE field is (or should be) increasingly becoming patient driven and 
manufacturing focused.   
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